Gilead Sciences has secured the rights to Sprint Bioscience’s preclinical oncology programme for up to $400m, sending Sprint’s stock soaring by more than 110%. This deal will see Gilead hand over $14m upfront for the three-prime repair exonuclease 1 (TREX1) blocker, which constitutes a novel immunotherapy approach. Through the agreement, Sprint could see up to $386m in regulatory, commercial and milestone payments, taking the deal’s total consideration up to $400m. In a 24 November statement, Sprint’s C ...